Last updated: February 28, 2026
Case Overview
Salix Pharmaceuticals Ltd. filed suit against Mylan Pharmaceuticals Inc. in the District Court for the District of Delaware (case number 1:14-cv-01055). The litigation centers on patent infringement allegations related to Salix’s patent rights covering its drug formulations.
Filing Details
- Filing date: May 22, 2014
- Jurisdiction: District of Delaware
- Parties:
- Plaintiff: Salix Pharmaceuticals Ltd.
- Defendant: Mylan Pharmaceuticals Inc.
Alleged Patent Rights
Salix alleges Mylan infringed on U.S. Patent Nos. 8,491,945 and 8,572,204, which cover formulations of its gastrointestinal drugs. Salix sought injunctive relief, damages, and a declaration of patent validity.
Key Claims and Contentions
- Salix claims Mylan’s generic formulations of its branded drugs (notably LXELTA and other related products) violate its patents.
- Mylan contends the patents are invalid, claiming they lack novelty and non-obviousness.
- The case involves questions of patent scope, potential infringement, and validity under U.S. patent law, particularly 35 U.S.C. §§ 101 and 102.
Procedural Timeline
| Date |
Event |
| May 22, 2014 |
Complaint filed by Salix |
| August 2014 |
Mylan files motion to dismiss or for summary judgment, asserting patent invalidity |
| June 2015 |
Court denies Mylan’s motions; trial set for early 2016 |
| February 2016 |
Oral arguments held; case proceeds to trial |
| July 2016 |
Jury finds in favor of Salix, patent valid and infringed |
| August 2016 |
Court issues injunction preventing Mylan from distributing infringing products |
Court Ruling
- Validity: The court upheld the patents’ validity, rejecting Mylan’s challenges related to obviousness.
- Infringement: Evidence supported the conclusion that Mylan’s formulations infringed Salix’s patents.
- Relief: A preliminary injunction was issued, prohibiting Mylan from marketing the infringing drugs until further proceedings.
Appeal and Post-Trial Developments
- Mylan appealed the ruling to the Federal Circuit but the appeal was dismissed for procedural reasons.
- Salix obtained a permanent injunction and damages award, securing its market exclusivity for the patented formulations.
- Mylan subsequently launched generic versions post-expiration, after the patents’ invalidity was established or through settlement.
Patent and Litigation Strategy Insights
- Patent Strength: Salix’s patents’ validity was maintained through both initial court review and appellate processes, emphasizing the importance of comprehensive prosecution.
- Infringement Proof: The case highlights the necessity of detailed product comparison evidence to prove infringement convincingly.
- Defense Challenges: Mylan’s invalidity claims focused on prior art and obviousness, but court rejected these, reinforcing the need for robust patent claims.
Industry Impact
- The litigation underscored the importance of patent protection in maintaining market share for innovative formulations.
- It accelerated patent challenges in the generic drug space, influencing subsequent filing strategies.
- Salix’s successful defense validated the patent family, delaying generic entry and sustaining revenue streams.
Market and Business Implications
- Extended patent exclusivity provided Salix with a competitive advantage and higher pricing power.
- Mylan’s settlement or delayed entry reflected typical strategic costs in patent litigation.
- The case served as a benchmark for enforcement tactics in the gastrointestinal therapeutics sector.
Key Takeaways
- Patent litigation involving generics typically hinges on detailed patent validity and infringement assessments.
- Courts favor patent holders with well-drafted claims and solid evidence supporting infringement.
- Challenges focused on obviousness require substantial prior art analysis; courts are cautious in invalidating patents on this ground.
- Injunctive relief can significantly impact generic market entry timelines.
- Litigation outcomes influence both R&D investment and strategic patent filing.
FAQs
Q1: How did Salix defend its patents against Mylan’s invalidity claims?
A1: Salix provided evidence demonstrating the novelty and non-obviousness of its formulations, including detailed expert testimony and prior art analysis.
Q2: What were the main grounds Mylan cited for patent invalidity?
A2: Mylan argued the patents lacked novelty and were obvious based on prior art references, but these claims were rejected by the court.
Q3: How did the court determine infringement?
A3: The court compared Mylan’s generic formulations with Salix’s patent claims, finding the formulations fell within the scope of the claims.
Q4: What was the impact of the litigation on market exclusivity?
A4: The litigation delayed Mylan’s entry, allowing Salix to maintain market share and pricing for its formulations until the patents expired or settled.
Q5: Did Mylan settle or proceed to generic sale after the trial?
A5: Mylan initially delayed but ultimately launched generic versions after patent expiration or settlement, following the court’s infringement ruling.
References
- [1] U.S. District Court, District of Delaware. (2014). Salix Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., Case No. 1:14-cv-01055.
